Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn whether tomotherapy will be able to deliver higher radiation doses safely to the tumor while sparing the surrounding normal tissue.

Inclusion Criteria:

• Histologically confirmed glioblastoma multiforme
• Ages 18-65
• Karnofsky Performance Scale (KPS) equal to or less than 70
• Minimal neurological deficit
• Eligible for concurrent temozolomide chemotherapy

Exclusion Criteria:

• Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer